116 related articles for article (PubMed ID: 18922422)
1. Monitoring recombinant factor VIIa treatment: efficacy depends on high levels of fibrinogen in a model of severe dilutional coagulopathy.
Ganter MT; Schmuck S; Hamiel CR; Wischmeyer PE; Heule D; Zollinger A; Hofer CK
J Cardiothorac Vasc Anesth; 2008 Oct; 22(5):675-80. PubMed ID: 18922422
[TBL] [Abstract][Full Text] [Related]
2. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
Tanaka KA; Taketomi T; Szlam F; Calatzis A; Levy JH
Anesth Analg; 2008 Mar; 106(3):732-8, table of contents. PubMed ID: 18292410
[TBL] [Abstract][Full Text] [Related]
3. Effect of hemodilution on coagulation and recombinant factor VIIa efficacy in human blood in vitro.
Darlington DN; Delgado AV; Kheirabadi BS; Fedyk CG; Scherer MR; Pusateri AE; Wade CE; Cap AP; Holcomb JB; Dubick MA
J Trauma; 2011 Nov; 71(5):1152-63. PubMed ID: 21610535
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIIa and fibrinogen display additive effect during in vitro haemodilution with crystalloids.
Fenger-Eriksen C; Tønnesen E; Ingerslev J; Sørensen B
Acta Anaesthesiol Scand; 2009 Mar; 53(3):332-8. PubMed ID: 19243319
[TBL] [Abstract][Full Text] [Related]
5. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA
Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
[TBL] [Abstract][Full Text] [Related]
6. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model.
Dickneite G; Dörr B; Kaspereit F; Tanaka KA
J Trauma; 2010 May; 68(5):1151-7. PubMed ID: 19996804
[TBL] [Abstract][Full Text] [Related]
7. High-dose fibrinogen versus a clinically recommended dose of fresh frozen plasma for reversal of dilutional coagulopathy in an in vitro model of severe hemodilution.
Rosenthal C; Rau J; Volk T; Sander M; Ziemer S; Von Heymann C
Minerva Anestesiol; 2014 Aug; 80(8):894-903. PubMed ID: 24398441
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Factor VIIa Reduces Bleeding after Blunt Liver Injury in a Pig Model of Dilutional Coagulopathy under Severe Hypothermia.
Spronk HM; Braunschweig T; Rossaint R; Wüst DC; van Oerle R; Lauritzen B; Tolba R; Grottke O
PLoS One; 2015; 10(6):e0113979. PubMed ID: 26098426
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIIa reduces bleeding after blunt liver injury in coagulopathic, hypofibrinogenaemic pigs.
Grottke O; Braunschweig T; Zimmermann L; Kopp R; Lauritzen B; Coburn M; Tolba R; Rossaint R
Br J Anaesth; 2010 Dec; 105(6):789-97. PubMed ID: 20926476
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
Sølbeck S; Nilsson CU; Engström M; Ostrowski SR; Johansson PI
Scand J Clin Lab Invest; 2014 Oct; 74(7):591-8. PubMed ID: 24909158
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
[TBL] [Abstract][Full Text] [Related]
12. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
[TBL] [Abstract][Full Text] [Related]
13. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: an in vitro model.
Fries D; Innerhofer P; Reif C; Streif W; Klingler A; Schobersberger W; Velik-Salchner C; Friesenecker B
Anesth Analg; 2006 Feb; 102(2):347-51. PubMed ID: 16428520
[TBL] [Abstract][Full Text] [Related]
14. Citrate artificially masks the haemostatic effect of recombinant factor VIIa in dilutional coagulopathy.
Fenger-Eriksen C; Ingerslev J; Tønnesen E; Sørensen B
Ann Hematol; 2009 Mar; 88(3):255-60. PubMed ID: 18696068
[TBL] [Abstract][Full Text] [Related]
15. In vitro effect of activated recombinant factor VII (rFVIIa) on coagulation properties of human blood at hypothermic temperatures.
Kheirabadi BS; Delgado AV; Dubick MA; Scherer MR; Fedyk CG; Holcomb JB; Pusateri AE
J Trauma; 2007 Nov; 63(5):1079-86. PubMed ID: 17993954
[TBL] [Abstract][Full Text] [Related]
16. The combination of recombinant factor VIIa and fibrinogen correct clotting ex vivo in patient samples obtained following cardiopulmonary bypass surgery.
Sørensen B; Asvaldsdottir HS; Gudmundsdottir BR; Onundarson PT
Thromb Res; 2009 Dec; 124(6):695-700. PubMed ID: 19733387
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram.
Lak M; Scharling B; Blemings A; Sharifian R; Maleki Z; Daraee A; Arjmand AR; Hedner U
Haemophilia; 2008 Jan; 14(1):103-10. PubMed ID: 18070065
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIIa is effective at reversing coagulopathy in a lactic acidosis model.
Lesperance RN; Lehmann RK; Harold DM; Beekley AC; Sebesta JA; Martin MJ
J Trauma Acute Care Surg; 2012 Jan; 72(1):123-9. PubMed ID: 22002618
[TBL] [Abstract][Full Text] [Related]
19. Free oscillation rheometry monitoring of haemodilution and hypothermia and correction with fibrinogen and factor XIII concentrates.
Winstedt D; Tynngård N; Olanders K; Schött U
Scand J Trauma Resusc Emerg Med; 2013 Mar; 21():20. PubMed ID: 23517637
[TBL] [Abstract][Full Text] [Related]
20. The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding.
Fries D
Transfusion; 2013 Jan; 53 Suppl 1():91S-95S. PubMed ID: 23301979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
